ReviewCurrent diabetes reports2005
Lipids and diabetic renal disease.
Review in Current diabetes reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.Diabetes care · 2010Trial
- Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney.Diabetes spectrum : a publication of the American Diabetes Association · 2021Article
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.Nature reviews. Nephrology · 2021Review
- Comparing the renoprotective effects of the antioxidants melatonin, vitamin D and vitamin E in diabetic rats.Journal of Taibah University Medical Sciences · 2020Article
- Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease.Frontiers in pharmacology · 2020Review
- New therapeutic agents in diabetic nephropathy.The Korean journal of internal medicine · 2017Review
- Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.The Journal of biological chemistry · 2016Article
- Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.Journal of lipid research · 2014Article
- Diabetes and its comorbidities--where East meets West.Nature reviews. Endocrinology · 2013Review
- Lipids and diabetic nephropathy.Current diabetes reports · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy is commonly associated with dyslipidemia, but the role of lipids in the progression of this disorder remains unresolved. In particular, the role of lipid-lowering drugs, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fibrates, as renoprotective agents is not clarified. Experimental studies have demonstrated that dietary lipids promote renal injury and that statins, independent of their lipid-lowering effects, confer renoprotection via effects on intrarenal hemodynamics and renal cytokine and chemokine expression. Clinical studies have in general been underpowered, but a recent meta-analysis and findings from the Heart Protection Study suggest that statins may be renoprotective. Nevertheless, with the convincing antiatherosclerotic effects of these agents, including in the setting of diabetes, they should be widely administered in the diabetic population with or at risk for nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.